Loden M - Search Results

1

High XIST and Low 53BP1 Expression Predict Poor Outcome after High-Dose Alkylating Chemotherapy in Patients with a BRCA1-like Breast Cancer.

Schouten PC, Vollebergh MA, Opdam M, Jonkers M, Loden M, Wesseling J, Hauptmann M, Linn SC. Schouten PC, et al. Among authors: loden m. Mol Cancer Ther. 2016 Jan;15(1):190-8. doi: 10.1158/1535-7163.MCT-15-0470. Epub 2015 Dec 4. Mol Cancer Ther. 2016. PMID: 26637364

2

Impact of intertumoral heterogeneity on predicting chemotherapy response of BRCA1-deficient mammary tumors.

Rottenberg S, Vollebergh MA, de Hoon B, de Ronde J, Schouten PC, Kersbergen A, Zander SA, Pajic M, Jaspers JE, Jonkers M, Lodén M, Sol W, van der Burg E, Wesseling J, Gillet JP, Gottesman MM, Gribnau J, Wessels L, Linn SC, Jonkers J, Borst P. Rottenberg S, et al. Among authors: loden m. Cancer Res. 2012 May 1;72(9):2350-61. doi: 10.1158/0008-5472.CAN-11-4201. Epub 2012 Mar 6. Cancer Res. 2012. PMID: 22396490 Free PMC article.

3

G1-S transition defects occur in most breast cancers and predict outcome.

Nielsen NH, Lodén M, Cajander J, Emdin SO, Landberg G. Nielsen NH, et al. Among authors: loden m. Breast Cancer Res Treat. 1999 Jul;56(2):105-12. doi: 10.1023/a:1006208419350. Breast Cancer Res Treat. 1999. PMID: 10573103

4

C-erbB2, p27 and G1/S aberrations in human primary breast cancer.

Lodén M, Perris F, Nielsen NH, Emdin SO, Landberg G. Lodén M, et al. Anticancer Res. 2003 May-Jun;23(3A):2053-61. Anticancer Res. 2003. PMID: 12894578

5

The impact of SF3B1 mutations in CLL on the DNA-damage response.

Te Raa GD, Derks IA, Navrkalova V, Skowronska A, Moerland PD, van Laar J, Oldreive C, Monsuur H, Trbusek M, Malcikova J, Lodén M, Geisler CH, Hüllein J, Jethwa A, Zenz T, Pospisilova S, Stankovic T, van Oers MH, Kater AP, Eldering E. Te Raa GD, et al. Among authors: loden m. Leukemia. 2015 May;29(5):1133-42. doi: 10.1038/leu.2014.318. Epub 2014 Nov 5. Leukemia. 2015. PMID: 25371178

6

Human heterochromatin proteins form large domains containing KRAB-ZNF genes.

Vogel MJ, Guelen L, de Wit E, Peric-Hupkes D, Lodén M, Talhout W, Feenstra M, Abbas B, Classen AK, van Steensel B. Vogel MJ, et al. Among authors: loden m. Genome Res. 2006 Dec;16(12):1493-504. doi: 10.1101/gr.5391806. Epub 2006 Oct 12. Genome Res. 2006. PMID: 17038565 Free PMC article.

7

Cyclin E dependent kinase activity in human breast cancer in relation to cyclin E, p27 and p21 expression and retinoblastoma protein phosphorylation.

Lodén M, Nielsen NH, Roos G, Emdin SO, Landberg G. Lodén M, et al. Oncogene. 1999 Apr 22;18(16):2557-66. doi: 10.1038/sj.onc.1202488. Oncogene. 1999. PMID: 10353599

8

The cyclin D1 high and cyclin E high subgroups of breast cancer: separate pathways in tumorogenesis based on pattern of genetic aberrations and inactivation of the pRb node.

Lodén M, Stighall M, Nielsen NH, Roos G, Emdin SO, Ostlund H, Landberg G. Lodén M, et al. Oncogene. 2002 Jul 11;21(30):4680-90. doi: 10.1038/sj.onc.1205578. Oncogene. 2002. PMID: 12096344

9

Long-term cultured IL-2-dependent T cell lines demonstrate p16(INK4a) overexpression, normal pRb/p53, and upregulation of cyclins E or D2.

Siwicki JK, Hedberg Y, Nowak R, Lodén M, Zhao J, Landberg G, Roos G. Siwicki JK, et al. Among authors: loden m. Exp Gerontol. 2000 May;35(3):375-88. doi: 10.1016/s0531-5565(00)00088-7. Exp Gerontol. 2000. PMID: 10832057

10

Whole-genome views of chromatin structure.

Lodén M, van Steensel B. Lodén M, et al. Chromosome Res. 2005;13(3):289-98. doi: 10.1007/s10577-005-2166-z. Chromosome Res. 2005. PMID: 15868422 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

75 results

Search Page